Jooli Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jooli Han has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Alicia Lau
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
2 shared publications - Ana Jaklenec
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
2 shared publications - Dennis Trumble
Allegheny-Singer Research Institute, Pittsburgh, PA 15212
2 shared publications - Linzixuan Zhang
Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, USA
2 shared publications - Robert Langer
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
2 shared publications - Shahad K. Alsaiari
David H. Koch Institute for Integrative Cancer Research Massachusetts Institute of Technology Cambridge Massachusetts USA
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 24 February 2025
- Published by Springer Nature in Nature Materials
- Vol. 24 (5) , 794-803
On-patient medical record and mRNA therapeutics using intradermal microneedles
Medical interventions often require timed series of doses, thus necessitating accurate medical record-keeping. In many global settings, these records are unreliable or unavailable at the point of care, leading to less effective treatments or disease prevention. Here we present an invisible-to-the-naked-eye on-patient medical record-keeping technology that accurately stores medical information in the patient skin as part of microneedles that are used for intradermal therapeutics. We optimize the microneedle design for both a reliable delivery of messenger RNA (mRNA) therapeutics and the near-infrared fluorescent microparticles that encode the on-patient medical record-keeping. Deep learning-based image processing enables encoding and decoding of the information with excellent temporal and spatial robustness. Long-term studies in a swine model demonstrate the safety, efficacy and reliability of this approach for the co-delivery of on-patient medical record-keeping and the mRNA vaccine encoding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This technology could help healthcare workers make informed decisions in circumstances where reliable record-keeping is unavailable, thus contributing to global healthcare equity.
- 24 February 2025
- Published by Springer Nature in Nature Materials
- Vol. 24 (5) , 794-803
Top Cited PapersOpen AccessOn-patient medical record and mRNA therapeutics using intradermal microneedles
Medical interventions often require timed series of doses, thus necessitating accurate medical record-keeping. In many global settings, these records are unreliable or unavailable at the point of care, leading to less effective treatments or disease prevention. Here we present an invisible-to-the-naked-eye on-patient medical record-keeping technology that accurately stores medical information in the patient skin as part of microneedles that are used for intradermal therapeutics. We optimize the microneedle design for both a reliable delivery of messenger RNA (mRNA) therapeutics and the near-infrared fluorescent microparticles that encode the on-patient medical record-keeping. Deep learning-based image processing enables encoding and decoding of the information with excellent temporal and spatial robustness. Long-term studies in a swine model demonstrate the safety, efficacy and reliability of this approach for the co-delivery of on-patient medical record-keeping and the mRNA vaccine encoding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This technology could help healthcare workers make informed decisions in circumstances where reliable record-keeping is unavailable, thus contributing to global healthcare equity.
- Open Access
- 6 December 2024
- Published by Springer Nature in Nature Chemical Engineering
- Vol. 2 (1) , 77-89
Degradable poly(β-amino ester) microparticles for cleansing products and food fortification
Microplastic pollution is a pressing global crisis caused by the extensive use of nondegradable microplastic materials in daily activities. One effective approach to mitigate this issue is to replace nondegradable plastics with degradable materials that have properties amendable for targeted applications. Here we present the development of a degradable microparticle (MP) platform based on a poly(β-amino ester) (PAE) that degrades into sugar and amino acid derivatives. This PAE MP platform showed functional replacement of nondegradable microplastics used in cleansing products and food fortification. In cleansing products, PAE MPs effectively enhanced the cleansing efficiency of a representative rinse-off product and showed effective removal of potentially toxic elements, as an alternative of traditional nondegradable microbeads. In food fortification, PAE MPs provided robust protection for multiple essential vitamins and minerals against extensive cooking and storage conditions with rapid nutrient release in a simulated human digestion system. Collectively, these PAE MPs present a potential platform to replace microplastic usage on a global scale in many applications.
- 6 December 2024
- Published by Springer Nature in Nature Chemical Engineering
- Vol. 2 (1) , 77-89
Open AccessDegradable poly(β-amino ester) microparticles for cleansing products and food fortification
Microplastic pollution is a pressing global crisis caused by the extensive use of nondegradable microplastic materials in daily activities. One effective approach to mitigate this issue is to replace nondegradable plastics with degradable materials that have properties amendable for targeted applications. Here we present the development of a degradable microparticle (MP) platform based on a poly(β-amino ester) (PAE) that degrades into sugar and amino acid derivatives. This PAE MP platform showed functional replacement of nondegradable microplastics used in cleansing products and food fortification. In cleansing products, PAE MPs effectively enhanced the cleansing efficiency of a representative rinse-off product and showed effective removal of potentially toxic elements, as an alternative of traditional nondegradable microbeads. In food fortification, PAE MPs provided robust protection for multiple essential vitamins and minerals against extensive cooking and storage conditions with rapid nutrient release in a simulated human digestion system. Collectively, these PAE MPs present a potential platform to replace microplastic usage on a global scale in many applications.
- 18 February 2020
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Biomedical Engineering
- Vol. 67 (11) , 3035-3047
Muscle-Powered Counterpulsation for Untethered, Non-Blood-Contacting Cardiac Support: A Path to Destination Therapy
Conventional long-term ventricular assist devices continue to be extremely problematic due to infections caused by percutaneous drivelines and thrombotic events associated with the use of blood-contacting surfaces. Here we describe a muscle-powered cardiac assist device that avoids both these problems by using an internal muscle energy converter to drive a non-blood-contacting extra-aortic balloon pump. The technology was developed previously in this lab and operates by converting the contractile energy of the latissimus dorsi muscle into hydraulic power that can be used, in principle, to drive any blood pump amenable to pulsatile actuation. The two main advantages of this implantable power source are that it 1) significantly reduces infection risk by avoiding a constant skin wound, and 2) improves patient quality-of-life by eliminating all external hardware components. The counterpulsatile balloon pumps, which compress the external surface of the ascending aorta during the diastolic phase of the cardiac cycle, offer another critical advantage in the setting of long-term circulatory support in that they increase cardiac output and improve coronary perfusion without touching the blood. The goal of this work is to combine these two technologies into a single circulatory support system that eliminates driveline complications and avoids surface-mediated thromboembolic events, thereby providing a safe, tether-free means to support the failing heart over extended - or even indefinite periods of time.
- 18 February 2020
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Biomedical Engineering
- Vol. 67 (11) , 3035-3047
Muscle-Powered Counterpulsation for Untethered, Non-Blood-Contacting Cardiac Support: A Path to Destination Therapy
Conventional long-term ventricular assist devices continue to be extremely problematic due to infections caused by percutaneous drivelines and thrombotic events associated with the use of blood-contacting surfaces. Here we describe a muscle-powered cardiac assist device that avoids both these problems by using an internal muscle energy converter to drive a non-blood-contacting extra-aortic balloon pump. The technology was developed previously in this lab and operates by converting the contractile energy of the latissimus dorsi muscle into hydraulic power that can be used, in principle, to drive any blood pump amenable to pulsatile actuation. The two main advantages of this implantable power source are that it 1) significantly reduces infection risk by avoiding a constant skin wound, and 2) improves patient quality-of-life by eliminating all external hardware components. The counterpulsatile balloon pumps, which compress the external surface of the ascending aorta during the diastolic phase of the cardiac cycle, offer another critical advantage in the setting of long-term circulatory support in that they increase cardiac output and improve coronary perfusion without touching the blood. The goal of this work is to combine these two technologies into a single circulatory support system that eliminates driveline complications and avoids surface-mediated thromboembolic events, thereby providing a safe, tether-free means to support the failing heart over extended - or even indefinite periods of time.
- Open Access
- 5 July 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (7) , e0219162
Ventricle-specific epicardial pressures as a means to optimize direct cardiac compression for circulatory support: A pilot study
Direct cardiac compression (DCC) holds enormous potential as a safe and effective means to treat heart failure patients who require long-term, or even permanent, biventricular support. However, devices developed to date are not tuned to meet the individual compression requirements of the left and right ventricles, which can differ substantially. In this paper, a systematic study examining the relationship, range, and effect of independent pressures on the left and right epicardial surfaces of a passive human heart model was performed as a means to optimize cardiac output via DCC support. Hemodynamic and tissue deformation effects produced by varying epicardial compressions were examined using finite element analysis. Results indicate that 1) designing a direct cardiac compression pump that applies separate pressures to the left and right ventricles is critical to maintain equivalent stroke volume for both ventricles, and 2) left and right ventricular epicardial pressures of 340 mmHg and 44 mmHg, respectively, are required to induce normal ejection fractions in a passive heart. This pilot study provides fundamental insights and guidance towards the design of improved direct cardiac compression devices for long-term circulatory support.
- 5 July 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (7) , e0219162
Open AccessVentricle-specific epicardial pressures as a means to optimize direct cardiac compression for circulatory support: A pilot study
Direct cardiac compression (DCC) holds enormous potential as a safe and effective means to treat heart failure patients who require long-term, or even permanent, biventricular support. However, devices developed to date are not tuned to meet the individual compression requirements of the left and right ventricles, which can differ substantially. In this paper, a systematic study examining the relationship, range, and effect of independent pressures on the left and right epicardial surfaces of a passive human heart model was performed as a means to optimize cardiac output via DCC support. Hemodynamic and tissue deformation effects produced by varying epicardial compressions were examined using finite element analysis. Results indicate that 1) designing a direct cardiac compression pump that applies separate pressures to the left and right ventricles is critical to maintain equivalent stroke volume for both ventricles, and 2) left and right ventricular epicardial pressures of 340 mmHg and 44 mmHg, respectively, are required to induce normal ejection fractions in a passive heart. This pilot study provides fundamental insights and guidance towards the design of improved direct cardiac compression devices for long-term circulatory support.
- Open Access
- 15 February 2019
- Published by MDPI AG in Bioengineering
- Vol. 6 (1) , 18
Cardiac Assist Devices: Early Concepts, Current Technologies, and Future Innovations
Congestive heart failure (CHF) is a debilitating condition that afflicts tens of millions of people worldwide and is responsible for more deaths each year than all cancers combined. Because donor hearts for transplantation are in short supply, a safe and durable means of mechanical circulatory support could extend the lives and reduce the suffering of millions. But while the profusion of blood pumps available to clinicians in 2019 tend to work extremely well in the short term (hours to weeks/months), every long-term cardiac assist device on the market today is limited by the same two problems: infections caused by percutaneous drivelines and thrombotic events associated with the use of blood-contacting surfaces. A fundamental change in device design is needed to address both these problems and ultimately make a device that can support the heart indefinitely. Toward that end, several groups are currently developing devices without blood-contacting surfaces and/or extracorporeal power sources with the aim of providing a safe, tether-free means to support the failing heart over extended periods of time.
- 15 February 2019
- Published by MDPI AG in Bioengineering
- Vol. 6 (1) , 18
Open AccessCardiac Assist Devices: Early Concepts, Current Technologies, and Future Innovations
Congestive heart failure (CHF) is a debilitating condition that afflicts tens of millions of people worldwide and is responsible for more deaths each year than all cancers combined. Because donor hearts for transplantation are in short supply, a safe and durable means of mechanical circulatory support could extend the lives and reduce the suffering of millions. But while the profusion of blood pumps available to clinicians in 2019 tend to work extremely well in the short term (hours to weeks/months), every long-term cardiac assist device on the market today is limited by the same two problems: infections caused by percutaneous drivelines and thrombotic events associated with the use of blood-contacting surfaces. A fundamental change in device design is needed to address both these problems and ultimately make a device that can support the heart indefinitely. Toward that end, several groups are currently developing devices without blood-contacting surfaces and/or extracorporeal power sources with the aim of providing a safe, tether-free means to support the failing heart over extended periods of time.